10 billion CFU · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Lactobacillus gasseri BNR17 is a proprietary probiotic strain isolated from human breast milk, specifically selected for its metabolic effects. It is one of the few probiotic strains with direct human RCT evidence for body composition improvement — particularly visceral fat and waist circumference reduction. Unlike general digestive probiotics, BNR17 targets adipose tissue metabolism and appetite regulation through the gut-brain axis.
BNR17 reduces visceral fat by inhibiting lipogenesis (fat creation) and promoting lipolysis (fat breakdown) in adipocytes. It modulates leptin and ghrelin signalling, potentially reducing appetite and improving satiety. A 2018 RCT in 90 overweight adults showed that 10 billion CFU/day BNR17 for 12 weeks significantly reduced visceral fat area (-14.6 cm²), waist circumference (-1.8 cm), hip circumference (-1.5 cm) and body weight (-1.4 kg) vs placebo. The strain also improved bowel habits and reduced bloating. Animal studies show it prevents diet-induced obesity and improves insulin sensitivity.
Overweight adults seeking a probiotic adjunct for body composition improvement. Those with central adiposity (belly fat) wanting targeted visceral fat reduction. Individuals with sluggish digestion and bloating alongside weight concerns. People interested in metabolic probiotics with human RCT validation. Not a replacement for diet and exercise.
Individuals with severe immunosuppression. Those with central venous catheters. Pregnant and breastfeeding women (safety not established in weight-loss RCTs). People with eating disorders. Not for children. Side effects: Generally well-tolerated. Mild bloating or gas in the first 1–2 weeks. Some users report increased bowel movements. No serious adverse events reported in RCTs. As with all probiotics, immunocompromised individuals should consult a physician.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 29688793 (12-week RCT visceral fat reduction, n=90), PMID 23382926 (anti-obesity in diet-induced obese mice), PMID 29381142 (mechanisms of action review), PMID 29381143 (adipocyte lipolysis mechanism)
SacredBod's longer take on Lactobacillus Gasseri BNR17 — context the structured blocks above don't capture.
Lactobacillus gasseri BNR17 is a proprietary probiotic strain isolated from human breast milk, specifically selected for its metabolic effects. It is one of the few probiotic strains with direct human RCT evidence for body composition improvement — particularly visceral fat and waist circumference reduction. Unlike general digestive probiotics, BNR17 targets adipose tissue metabolism and appetite regulation through the gut-brain axis.
BNR17 reduces visceral fat by inhibiting lipogenesis (fat creation) and promoting lipolysis (fat breakdown) in adipocytes. It modulates leptin and ghrelin signalling, potentially reducing appetite and improving satiety. A 2018 RCT in 90 overweight adults showed that 10 billion CFU/day BNR17 for 12 weeks significantly reduced visceral fat area (-14.6 cm²), waist circumference (-1.8 cm), hip circumference (-1.5 cm) and body weight (-1.4 kg) vs placebo. The strain also improved bowel habits and reduced bloating. Animal studies show it prevents diet-induced obesity and improves insulin sensitivity.
Overweight adults seeking a probiotic adjunct for body composition improvement. Those with central adiposity (belly fat) wanting targeted visceral fat reduction. Individuals with sluggish digestion and bloating alongside weight concerns. People interested in metabolic probiotics with human RCT validation. Not a replacement for diet and exercise.
Typical dose: 10 billion CFU per day
Form: capsules (60 count)
Best time: morning
With food: with-food
Expected onset: 4–8 weeks for body composition changes; 12 weeks for maximal fat reduction
Cycling: No cycling required. Continuous daily use supported by 12-week RCT data.
Known side effects: Generally well-tolerated. Mild bloating or gas in the first 1–2 weeks. Some users report increased bowel movements. No serious adverse events reported in RCTs. As with all probiotics, immunocompromised individuals should consult a physician.
Who should avoid: Individuals with severe immunosuppression. Those with central venous catheters. Pregnant and breastfeeding women (safety not established in weight-loss RCTs). People with eating disorders. Not for children.
Avoid combining with: Antibiotics (take 2 hours apart), Immunosuppressants, Weight loss medications (theoretical additive effect), Other metabolic probiotics (redundant)
Lactobacillus Gasseri BNR17 is available on Amazon India with varying brand quality. When selecting a probiotic, verify CFU count at expiry (not just at manufacture), strain specificity and refrigeration requirements. Indian brand preferences include Tata 1mg, ZEROHARM, Carbamide Forte, HealthKart, Jarrow Formulas, Now Foods, and Meibotan. Prices vary significantly; compare cost-per-CFU rather than capsule count alone.
Schedule status in India: Not a Schedule H drug; available as dietary supplement.
Key citations: PMID 29688793 (12-week RCT visceral fat reduction, n=90), PMID 23382926 (anti-obesity in diet-induced obese mice), PMID 29381142 (mechanisms of action review), PMID 29381143 (adipocyte lipolysis mechanism)
Evidence grade: B — n=90 in primary body composition RCT; multiple animal studies
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
